Two women in Louisiana required emergency medical care after obtaining mifepristone under the FDA's loosened access rules. The Medicaid bills totaled $92,000. Louisiana's 72-page complaint in the case known as Louisiana v. FDA laid out what the state called "numerous illegal abortions in Louisiana" — all flowing from the FDA's 2023 decision to gut its own safety requirements for the drug.

The Fifth Circuit Court of Appeals just froze those rules in place.

The injunction upends the current status quo on mifepristone distribution, which had been operating under changes the FDA made in 2023 to its Risk Evaluation and Mitigation Strategy — the REMS framework that governs how high-risk drugs reach patients. Before 2023, mifepristone required in-person dispensing. The FDA eliminated that requirement, opening the door to mail-order abortion pills with no in-person medical supervision.

Louisiana filed suit against the FDA, and the state wasn't alone. Twenty-one state attorneys general filed briefs supporting Louisiana's position. Sixty members of Congress did the same. The legal coalition arguing that the FDA overstepped wasn't a fringe effort — it was a coordinated challenge backed by a majority of red-state legal infrastructure.

Louisiana's attorney general framed the state's position around restoring "pre-Biden era rules" and what the office called "good common sense" — specifically, the requirement that a woman see a doctor in person before being prescribed a drug that carries known risks of hemorrhage, incomplete abortion, and infection. The $92,000 in emergency Medicaid costs from just two cases illustrated the state's argument in dollar terms the federal government couldn't wave away.

The plaintiff Rosalie Markezich, an individual named in Louisiana's lawsuit, put a personal face on the legal challenge — someone directly affected by the FDA's decision to relax safeguards that had been in place for over two decades.

The FDA's 2023 REMS changes were supposed to be about "access." The word did a lot of heavy lifting. What the changes actually did was remove the medical gatekeeping that existed precisely because mifepristone isn't aspirin. It's a two-drug regimen that ends a pregnancy and carries complications serious enough that the FDA itself originally required supervised dispensing. The agency didn't discover new safety data in 2023 that justified the rollback. The political environment changed.

After the Dobbs decision returned abortion regulation to the states, the mail-order pill became the preferred workaround for those who didn't much care what the states had decided. Pills shipped across state lines, into jurisdictions that had passed restrictions through their own legislatures. The Fifth Circuit's injunction doesn't just freeze FDA rules — it reasserts that states enforcing their own laws aren't powerless against a federal agency rewriting the regulatory landscape to nullify those laws.

Twenty-one attorneys general and sixty members of Congress lined up behind a 72-page complaint documenting real costs and real consequences. The Fifth Circuit read it and agreed there was enough to freeze the FDA's hand.

The pill was supposed to be the one door Dobbs couldn't close. Turns out, it wasn't the court's door to begin with.